Sameeksha Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 M
as on 16-11-2024
- Revenue 1196.55%
(FY 2023)
- Profit 6815.04%
(FY 2023)
- Ebitda 549.60%
(FY 2023)
- Net Worth 3703.28%
(FY 2023)
- Total Assets 415.90%
(FY 2023)
About Sameeksha Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Samiksha Gaikwad and Samir Gaikwad serve as directors at the Company.
- CIN/LLPIN
U24302PN2016PTC164262
- Company No.
164262
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sameeksha Pharmaceuticals Private Limited offer?
Sameeksha Pharmaceuticals Private Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets.
Who are the key members and board of directors at Sameeksha Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samir Gaikwad  | Director | 01-May-2016 | Current |
| Samiksha Gaikwad | Director | 01-May-2016 | Current |
Financial Performance of Sameeksha Pharmaceuticals.
Sameeksha Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1196.55% increase. The company also saw a substantial improvement in profitability, with a 6815.04% increase in profit. The company's net worth Soared by an impressive increase of 3703.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sameeksha Pharmaceuticals?
In 2021, Sameeksha Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zyrex Healthcare Private LimitedActive 2 years 4 monthsSamiksha Gaikwad and Samir Gaikwad are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 May 2024 | ₹5.00 M | Open |
How Many Employees Work at Sameeksha Pharmaceuticals?
Unlock and access historical data on people associated with Sameeksha Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sameeksha Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sameeksha Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
